What Is Peptide Therapy? An Honest Definition (2026)

Peptide therapy is the use of peptides — short chains of amino acids that act as signaling molecules in the body — as treatment. That is the literal definition, and it describes a real, century-old drug class: insulin therapy began in the 1920s, and over 60 peptide drugs are approved in the United States and other major markets, with more than 150 in active clinical development¹. But that is not what the phrase means in practice. As sold by wellness and telehealth clinics, "peptide therapy" is a marketing umbrella stretched over three legally and scientifically different things: FDA-approved peptide medicines, compounded prescription peptides whose legal status is in flux, and research chemicals with no approved product, whose human evidence is measured in pilot studies. The word "therapy" is doing the work of making those three sound like one — and you will not find the phrase on an insulin label or in a semaglutide trial, which tells you who the term is for.

This page defines the term by unpacking it: what sits in each bin, who regulates it, what the evidence actually supports, and how the clinics selling it operate.

What Does Peptide Therapy Actually Mean?

Start with the noun. A peptide is a short amino-acid chain — the same building blocks as proteins, just fewer of them — that typically works by binding a receptor and telling a cell to change behavior. The biology is covered properly in what peptides do for the body; the one fact to carry forward is that "peptide" describes a molecule's structure, not its legal status, its evidence base, or its safety. Insulin is a peptide. So is the unlabeled powder in a research vial. The word connects them; nothing else does.

Now the modifier. "Therapy" implies a treatment with a known effect, given for a reason, by someone accountable for the outcome. Whether that implication is earned depends entirely on which bin the compound sits in — so the honest way to define peptide therapy is to sort the market.

Bin 1: FDA-Approved Peptide Drugs

The first bin is real medicine, and it is bigger than most shoppers realize because its biggest products are rarely marketed under the peptide banner.

Semaglutide and tirzepatide — the drugs in Ozempic, Wegovy, Mounjaro and Zepbound — are peptides, engineered analogs of the gut incretin hormones that amplify insulin secretion after eating². We walk through that identity in is Ozempic a peptide?. Their evidence is the strongest in this entire subject: in STEP 1, once-weekly semaglutide produced a mean body-weight change of −14.9% over 68 weeks versus −2.4% on placebo in 1,961 adults³, and in SURMOUNT-1, tirzepatide reached −20.9% at its highest dose over 72 weeks versus −3.1% on placebo in 2,539 adults⁴.

The bin also contains narrower drugs. Tesamorelin, a growth-hormone-releasing factor analog, reduced visceral adipose tissue by 15.2% over 26 weeks in a 412-patient randomized trial in people with HIV-associated abdominal fat accumulation⁵ and is FDA-approved for exactly that indication — its label is explicit that it is not indicated for weight loss⁶. Dosing mechanics are in tesamorelin dosage. And insulin is the original member: the molecule that made peptides a drug class in the first place¹.

What defines this bin is not the molecules but the standard: a specific product, tested in controlled trials for a specific condition, manufactured under FDA oversight, prescribed on-label or off-label by a clinician. When a clinic's offer sits here — say, a ranked comparison of tirzepatide providers — the open questions are price and service, not whether the drug works.

Bin 2: Compounded Prescription Peptides

The second bin is where most of what is actually sold as "peptide therapy" lives, and its defining feature is a legal gray zone.

Compounded drugs are made by licensed pharmacies for individual prescriptions under sections 503A and 503B of the Food, Drug, and Cosmetic Act. They are legal to prescribe and dispense under conditions — but they are not FDA-approved products, even when the pharmacy is licensed and the prescription is real. Which peptides can be compounded at all depends on FDA's bulk-substances lists: nominated substances are sorted into categories, and FDA has identified significant safety risks for the substances it placed in category 2, which it says should not be compounded pending further evaluation¹². Ipamorelin acetate, for example, was placed in category 2 in September 2023, with FDA citing immunogenicity risk and a published report of serious adverse events, including death, when ipamorelin was administered intravenously¹³. The machinery is explained in what is the 503A bulks list?, and the current status of each compound is tracked against the primary record in our peptide FDA status tracker.

The flagship example is sermorelin, a growth-hormone-releasing hormone analog with a genuine clinical literature⁷ that today exists in the US almost entirely as a compounded product — prescribed through telehealth, mixed by a compounding pharmacy, never FDA-approved in that form. We compare its sellers on the sermorelin provider ranking and cover the numbers in sermorelin dosage.

This bin is also legally unstable by design. Compounded semaglutide and tirzepatide boomed during the FDA shortage listings and contracted when FDA declared the supply stabilized and clarified that compounders must stop making what are essentially copies of available approved drugs¹⁴ — the whole saga is in is compounded semaglutide still legal?, and a 2026 advisory committee vote reshuffled several peptides again, covered in the FDA peptide advisory vote. A clinic selling from this bin is selling something that can become unavailable, or newly available, by rulemaking.

Bin 3: Research Chemicals With No Approved Product

The third bin has no prescriptions, no pharmacies and no oversight — vials sold online "for research purposes only" as a legal posture while marketed for human use.

Its best-known residents are the recovery peptides. BPC-157 has demonstrated regenerative effects across numerous animal models, but a 2025 review states the human position plainly: only three pilot studies have examined it in humans, and it should be considered investigational⁹ — the full accounting is in BPC-157 recovery evidence. TB-500 repeats the shape with a further complication about which molecule is even in the vial, covered in TB-500 recovery evidence. Ipamorelin, first characterized in 1998 as a selective growth-hormone secretagogue in animal and in-vitro work⁸, never became an FDA-approved drug — see ipamorelin side effects for what is and is not known.

No agency verifies what these vials contain. The purchase legality question — legal to sell for research, not legal to sell for human use — is worked through in where to buy peptides and research chemical legality, and the vendor-side quality problem in how to verify a peptide COA.

Does the Evidence Support the Word "Therapy"?

Sorted this way, the answer stops being one answer.

In bin 1, yes — that is what approval means. In bin 3, no: calling three pilot studies "therapy" is a category error, whatever the animal data suggests.

Bin 2 is the interesting case, because the compounds are real drugs with real pharmacology and the gap is between the marker and the outcome. The GH-axis peptides genuinely raise growth hormone and IGF-1. But a systematic review of 27 controlled study samples in fit young adults found GH increased lean body mass by about 2.1 kg while strength and exercise capacity did not appear to improve, and concluded that claims of enhanced physical performance are not supported by the literature¹⁰. In healthy older adults, a companion review found small body-composition changes, increased rates of adverse events, and no basis for recommending GH as an anti-aging therapy¹¹. Raising the hormone is demonstrated; the benefit people are buying — recovery, muscle, youth — is not. That surrogate-marker gap is the running theme of GH peptides and recovery, and the goal-by-goal accounting is in what are peptides good for?.

How Do Telehealth Peptide Clinics Actually Work?

The commercial machine behind the phrase is remarkably uniform. You fill out an intake form. A clinician — usually asynchronous, sometimes a video call — approves a prescription. A compounding pharmacy, often an unnamed partner rather than a facility you can look up, ships vials, syringes and bacteriostatic water. Billing is a subscription, and the subscription is where the traps live.

Two verified examples show the range, as of August 2026. At the transparent end, CoreAge Rx sells sermorelin from $99 a month with no membership fee and its "upfront pricing, no hidden fees" stated on the product page — with the honest qualifiers that "starting at $99" is not a flat $99 and the compounding pharmacy is an unnamed partner network. In the middle sits a subtler pattern: Invigor Medical publishes a genuine itemized price list — sermorelin at $220.50 for 8 mg with consult and supplies included — but bills every four weeks rather than monthly, which quietly produces thirteen charges a calendar year instead of twelve: about $2,866 a year on the 8 mg plan, not the $2,640 a monthly reading implies.

That is why our comparisons price the true month-to-month cost rather than the advertised headline — an advertised "month" is frequently a four-week cycle, a first-month teaser, or a medication price sitting on top of an undisclosed membership. The per-provider figures live in the price transparency index.

Who Regulates What — and the Athlete Exception

Regulation follows the bins. FDA approves and inspects the products in bin 1. Bin 2 is split between state pharmacy licensure and FDA's compounding rules and lists¹². Bin 3 answers to no drug regulator at all in any way that touches product quality.

Anti-doping rules do not follow the bins — they are stricter. BPC-157 is prohibited in tested sport under the WADA list's catch-all for non-approved substances¹⁵, and the GH-releasing peptides are banned year-round regardless of whether a licensed clinician prescribed them. A prescription is not an exemption. If you compete in tested sport, check any compound against our WADA prohibited-substance checker before anything else.

How to Evaluate a Clinic Selling Peptide Therapy

The single most useful habit is to ask which bin each product on the menu belongs to, because clinics routinely present all three in one visual register — same cards, same fonts, same "therapy" label on an approved drug, a compounded gray-zone product and a research chemical. A menu that mixes bins without saying so is itself a signal, and the broader warning signs are cataloged in peptide vendor red flags.

The Bottom Line

Peptide therapy is not one thing. It is a marketing umbrella over three bins: approved peptide drugs with controlled-trial evidence, compounded prescription peptides that are legal but not FDA-approved and whose availability shifts with rulemaking, and research chemicals with essentially no human data sold outside regulation entirely¹⁹¹². The phrase tells you a clinic's positioning; the bin tells you what you are actually buying. Sort first, then evaluate — and if a seller will not make the sorting easy, that is your evaluation.

This page is educational and not medical advice. Whether any of these compounds is appropriate for you is a decision for a licensed clinician who knows your history.